Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Type:
Grant
Filed:
October 26, 2021
Date of Patent:
April 16, 2024
Assignee:
PROGENA INC.
Inventors:
Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov
Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Type:
Application
Filed:
October 26, 2021
Publication date:
February 10, 2022
Applicant:
PROGENA INC.
Inventors:
Alexander FESKOV, Irina FESKOVA, Ievgeniia ZHYLKOVA, Stanislav ZHILKOV
Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
November 30, 2021
Assignee:
PROGENA INC.
Inventors:
Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov
Abstract: A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Type:
Application
Filed:
July 9, 2021
Publication date:
October 28, 2021
Applicant:
PROGENA INC.
Inventors:
Alexander FESKOV, Ievgeniia ZHYLKOVA, Stanislav ZHILKOV, Irina FESKOVA, Vladislav FESKOV
Abstract: A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Type:
Grant
Filed:
August 28, 2017
Date of Patent:
August 17, 2021
Assignee:
Progena Inc.
Inventors:
Alexander Feskov, Ievgeniia Zhylkova, Stanislav Zhilkov, Irina Feskova, Vladislav Feskov
Abstract: A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Type:
Application
Filed:
August 28, 2017
Publication date:
March 1, 2018
Applicant:
Progena Inc.
Inventors:
Alexander FESKOV, Ievgeniia ZHYLKOVA, Stanislav ZHILKOV, Irina FESKOVA, Vladislav FESKOV